ASH 2023 | Bezuclastinib in adult patients with non-advanced systemic mastocytosis: initial results from Summit
Prithviraj Bose, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives an update from Summit (NCT05186753), an ongoing Phase II trial evaluating the safety and efficacy of bezuclastinib, a potent KIT D816V inhibitor, in adult patients with non-advanced systemic mastocytosis (NonAdvSM). This study enrolled patients with both indolent and smoldering disease. Initial results from a 20-patient sample with moderate to severe disease burden indicate that the drug is well-tolerated at both doses tested (100mg and 200mg) and is associated with encouraging clinical activity and a profound reduction in disease markers. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: GSK, Novartis, Karyopharm, AbbVie, Pharma Essentia, Jubilant, Morphic, Incyte, BMS, CTI, Morphosys, Blueprint, Cogent, Sumitomo, Ionis
Research Funding: Kartos, Telios, Disc, Janssen, Geron, Incyte, BMS, CTI, Morphosys, Blueprint, Cogent, Sumitomo, Ionis
